Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma

The advent of T-cell redirecting strategies, including chimeric antigen receptor T cells and bispecific antibodies, has significantly improved the prognosis of patients with relapsed/refractory large B-cell lymphoma. Current, ongoing clinical trials are exploring their role in earlier treatment lines, rapidly reshaping the treatment landscape of this disease entity. The field has shifted from the concept of transplant-eligible to chimeric antigen receptor T-cell eligible, albeit current trials still consider the former to define the target patient population. Here, we discuss 2 clinical cases to deliberately illustrate this dynamic era of T-cell redirecting strategies, highlighting the main learning points but also presenting the opportunities and open questions to be addressed in the future.